Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Ani Marrs

Senior Marketing Manager - Entellect

About the author: I’m currently responsible for Entellect – Elsevier’s data integration platform, designed to help pharma, chemicals and other Life Science organisations by enriching and harmonizing proprietary and external data so that their researchers can focus on answering the bigger questions that will improve patient outcomes. I’m particularly interested in the increase in predictive analytics within drug discovery, FAIR data and how new insights can be gleaned when information is connected across silos.

Posts by Ani Marrs

Partnering to identify repurposing candidates for chronic pancreatitis

Posted on May 12th, 2020 in Pharma R&D

Take a look at this infographic demonstrating how leveraging Entellect and collaborating with three partners led to a datathon that delivered four potential repurposing candidates in just 60 days.


Bridging information silos the FAIR way

Posted on February 3rd, 2020 in Pharma R&D

We are living in a unique time, when the combination of computational power, expertise in knowledge engineering, and the data generation rate are all aligned to enable the aggregating and analyzing of data from different sources and types in order to better understand life science systems. The incredibly data-rich workflows that result from this alignment can be used to get improved insights into diseases, in turn helping researchers to develop more efficient and effective treatments for those diseases.


How can we get pharma R&D to embrace FAIR data?

Posted on January 6th, 2020 in Pharma R&D

FAIR data, which is Findable, Accessible, Interoperable and Reusable, has the power to transform the analyses enabling drug discovery and development—yet, the pharma industry has been slow to adopt it. There are a number of reasons for this unfortunate reality, but there is a path to realizing the potential for FAIR data in pharmaceutical R&D.